

Alan J Camm

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3610060/alan-j-camm-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

462 papers	51,910 citations	86 h-index	225 g-index
527 ext. papers	62,564 ext. citations	5.8 avg, IF	7.05 L-index

#	Paper	IF	Citations
462	Do baseline characteristics and treatments account for geographical disparities in the outcomes of patients with newly diagnosed atrial fibrillation? The prospective GARFIELD-AF registry.. <i>BMJ Open</i> , 2022 , 12, e049933	3	0
461	Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration.. <i>Circulation</i> , 2022 , 145, 392-409	16.7	4
460	Rare Variation in Drug Metabolism and Long QT Genes and the Genetic Susceptibility to Acquired Long QT Syndrome.. <i>Circulation Genomic and Precision Medicine</i> , 2022 , CIRCGEN121003391	5.2	0
459	Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm.. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022 , CIRCEP121010204	6.4	1
458	AIM-AF: A Physician Survey in the United States and Europe.. <i>Journal of the American Heart Association</i> , 2022 , e023838	6	0
457	History and evolution of pacing and devices.. <i>Heart</i> , 2022 , 108, 794-799	5.1	0
456	The Increasing Role of Rhythm Control in Patients With Atrial Fibrillation: JACC State-of-the-Art Review.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 1932-1948	15.1	5
455	Multi-catheter cryotherapy compared with radiofrequency ablation in long-standing persistent atrial fibrillation: a randomized clinical trial. <i>Europace</i> , 2021 , 23, 370-379	3.9	4
454	Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data. <i>BMJ, The</i> , 2021 , 375, e066450	5.9	0
453	Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2021 , 23, 329-344	3.9	14
452	Improving the diagnosis of heart failure in patients with atrial fibrillation. <i>Heart</i> , 2021 , 107, 902-908	5.1	3
451	The RACE to the EAST. In pursuit of rhythm control therapy for atrial fibrillation-a dedication to Harry Crijns. <i>Europace</i> , 2021 , 23, ii34-ii39	3.9	1
450	Antiarrhythmic drugs for atrial fibrillation: lessons from the past and opportunities for the future. <i>Europace</i> , 2021 , 23, ii14-ii22	3.9	2
449	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. <i>Europace</i> , 2021 , 23, 1612-1676	3.9	99
448	Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD-AF Registry. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2322-2334	15.4	2
447	Persistent Atrial Fibrillation: The Role of Left Atrial Posterior Wall Isolation and Ablation Strategies. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
446	Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial. <i>Europace</i> , 2021 , 23, 65-72	3.9	

445	Changing paradigms: from prevention of thromboembolic events to improved survival in patients with atrial fibrillation. <i>Europace</i> , 2021 , 23, 837-843	3.9	5
444	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the	9.5	1676
443	Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation - results from the GARFIELD-AF registry. <i>Annals of Medicine</i> , 2021 , 53, 485-494	1.5	
442	Use of Non-vitamin K Antagonist Oral Anticoagulants for Stroke Prevention across the Stroke Spectrum: Progress and Prospects. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 716-730	7	1
441	Should we make the risk stratification process more complex in patients with atrial fibrillation? Authors' reply. <i>Europace</i> , 2021 , 23, 978-979	3.9	
440	Comparative effectiveness of oral anticoagulants in everyday practice. <i>Heart</i> , 2021 ,	5.1	5
439	Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry. <i>Blood Advances</i> , 2021 , 5, 1081-1091	7.8	8
438	Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the Arg389Arg Genotype. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021 , 14, e009591	6.4	1
437	Reexamination of the Embolic Stroke of Undetermined Source Concept. <i>Stroke</i> , 2021 , 52, 2715-2722	6.7	1
436	Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus. <i>Europace</i> , 2021 , 23, 1873-1891	3.9	2
435	Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. <i>European Heart Journal</i> , 2021 ,	9.5	10
434	Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure. <i>Circulation</i> , 2021 , 144, 845-858	16.7	14
433	Evaluation of the Switch From Amiodarone to Dronedarone in Patients With Atrial Fibrillation: Results of the ARTEMIS AF Studies. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020 , 25, 425-437	2.6	
432	Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation. <i>JAMA Network Open</i> , 2020 , 3, e200107	10.4	11
431	Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban. <i>Journal of the American Heart Association</i> , 2020 , 9, e009530	6	10
430	Continued misuse of orphan drug legislation: a life-threatening risk for mexiletine. <i>European Heart Journal</i> , 2020 , 41, 614-617	9.5	6
429	Left atrial appendage occlusion with the Amplatzer [®] Amulet [®] Device: full results of the prospective global observational study. <i>European Heart Journal</i> , 2020 , 41, 2894-2901	9.5	41
428	The year in cardiology: arrhythmias and pacing?The year in cardiology 2019. <i>Cardiologia Croatica</i> , 2020 , 15, 132-145	0	

427	Concomitant diabetes with atrial fibrillation and anticoagulation management considerations. <i>European Heart Journal Supplements</i> , 2020 , 22, O78-O86	1.5	5
426	Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group. <i>European Heart Journal</i> , 2020 , 41, 1132-1140	9.5	16
425	Time-trends and treatment gaps in the antithrombotic management of patients with atrial fibrillation after percutaneous coronary intervention: Insights from the CHUM AF-STENT Registry. <i>Clinical Cardiology</i> , 2020 , 43, 216-221	3.3	4
424	The year in cardiology: arrhythmias and pacing. <i>European Heart Journal</i> , 2020 , 41, 619-625c	9.5	2
423	Impact of oral anticoagulation in patients with atrial fibrillation at very low thromboembolic risk. <i>Heart</i> , 2020 , 106, 845-851	5.1	1
422	The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events. <i>Europace</i> , 2020 , 22, 195-204	3.9	13
421	Identification of undiagnosed atrial fibrillation patients using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI): Study protocol for a randomised controlled trial. <i>Contemporary Clinical Trials</i> , 2020 , 99, 106191	2.3	2
420	Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real-world prospective study. <i>Clinical Cardiology</i> , 2020 , 43, 1405-1413	3.3	2
419	Machine learning does not improve upon traditional regression in predicting outcomes in atrial fibrillation: an analysis of the ORBIT-AF and GARFIELD-AF registries. <i>Europace</i> , 2020 , 22, 1635-1644	3.9	7
418	Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2020 , 383, 1305-1316	59.2	337
417	Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 2497-2508	27.4	35
416	The New CHEST Guidelines on Antithrombotic Therapy for Atrial Fibrillation Should Consider Recent Data on Rivaroxaban. <i>Chest</i> , 2019 , 155, 1309-1311	5.3	
415	Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. <i>European Heart Journal</i> , 2019 , 40, 3013-3021	9.5	75
414	International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER). <i>Thrombosis Journal</i> , 2019 , 17, 7	5.6	7
413	Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. <i>American Heart Journal</i> , 2019 , 213, 35-46	4.9	28
412	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry. <i>Journal of the American Heart Association</i> , 2019 , 8, e010510	6	24
411	A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019 , 5, 21-28	6.4	12
410	Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS. <i>Europace</i> , 2019 , 21, 421-427	3.9	2

409	Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation. <i>Europace</i> , 2019 , 21, 1764-1775	3.9	5
408	Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF. <i>American Journal of Medicine</i> , 2019 , 132, 1431-1440.e7	2.4	5
407	Clinical utility of magnetocardiography in cardiology for the detection of myocardial ischemia. <i>Journal of Electrocardiology</i> , 2019 , 57, 10-17	1.4	6
406	GARFIELD-AF model for prediction of stroke and major bleeding in atrial fibrillation: a Danish nationwide validation study. <i>BMJ Open</i> , 2019 , 9, e033283	3	8
405	Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2204-2215	15.1	45
404	EHRA White Paper: knowledge gaps in arrhythmia management-status 2019. <i>Europace</i> , 2019 , 21, 993-994.	3.9	23
403	Impact of stable angina on health status and quality of life perception of currently treated patients. The BRIDGE 2 survey. <i>European Journal of Internal Medicine</i> , 2019 , 70, 60-67	3.9	6
402	Stable Angina: Perception of Needs, Quality of Life and Management of Patients (BRIDGE Study)-A Multinational European Physician Survey. <i>Angiology</i> , 2019 , 70, 397-406	2.1	5
401	Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019 , 5, 70-79	6.4	20
400	Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation. <i>Circulation</i> , 2019 , 139, 787-798	16.7	39
399	EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. <i>Europace</i> , 2019 ,	3.9	59
398	Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for rivaroxaban. <i>Current Medical Research and Opinion</i> , 2018 , 34, 1945-1957	2.5	2
397	Time trends in antithrombotic management of patients with atrial fibrillation treated with coronary stents: Results from TALENT-AF (The international stENT - Atrial Fibrillation study) multicenter registry. <i>Clinical Cardiology</i> , 2018 , 41, 470-475	3.3	11
396	Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study. <i>Clinical Cardiology</i> , 2018 , 41, 440-449	3.3	11
395	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. <i>Europace</i> , 2018 , 20, e1-e160	3.9	461
394	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. <i>Europace</i> , 2018 , 20, 157-208	3.9	227
393	The influence of progression of atrial fibrillation on quality of life: a report from the Euro Heart Survey. <i>Europace</i> , 2018 , 20, 929-934	3.9	15
392	Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care. <i>BMJ, The</i> , 2018 , 360, k342	5.9	50

391	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. <i>Europace</i> , 2018 , 20, 1231-1242	3.9	148
390	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018 , 39, 1330-1393	3.5	1094
389	Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study. <i>Europace</i> , 2018 , 20, e87-e95	3.9	11
388	Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention. <i>Europace</i> , 2018 , 20, 1-11	3.9	35
387	Cardiac Potassium Channels: Physiological Insights for Targeted Therapy. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018 , 23, 119-129	2.6	36
386	Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden. <i>Heart Rhythm</i> , 2018 , 15, 376-383	6.7	55
385	XANAP: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia. <i>Journal of Arrhythmia</i> , 2018 , 34, 418-427	1.5	12
384	Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the global anticoagulant registry in the FIELD-Atrial Fibrillation (GARFIELD-AF). <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2018 , 4, 27-35	4.6	8
383	Strengths and weaknesses of 'real-world' studies involving non-vitamin K antagonist oral anticoagulants. <i>Open Heart</i> , 2018 , 5, e000788	3	51
382	Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey). <i>American Journal of Cardiology</i> , 2018 , 122, 578-583	3	8
381	Global Prospective Safety Analysis of Rivaroxaban. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 141-153	15.1	35
380	Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS. <i>Revista Espanola De Cardiología</i> , 2017 , 70, 50.e1-50.e84	1.5	6
379	The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 777-785	15.1	193
378	Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. <i>Heart</i> , 2017 , 103, 307-314	5.1	163
377	Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. <i>BMJ Open</i> , 2017 , 7, e014579	3	22
376	Screening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration. <i>Circulation</i> , 2017 , 135, 1851-1867	16.7	302
375	Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. <i>American Heart Journal</i> , 2017 , 189, 137-145	4.9	170
374	Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. <i>American Heart Journal</i> , 2017 , 190, 12-18	4.9	143

373	Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017 , 3, 147-150	6.4	14
372	Viewpoint: Stroke Prevention in Recent Guidelines for the Management of Patients with Atrial Fibrillation: An Appraisal. <i>American Journal of Medicine</i> , 2017 , 130, 773-779	2.4	4
371	Hopes and disappointments with antiarrhythmic drugs. <i>International Journal of Cardiology</i> , 2017 , 237, 71-74	3.2	25
370	Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel-group, phase I study in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1011-1027	3.8	26
369	Antiarrhythmic Drug Management of Atrial Fibrillation. <i>Cardiovascular Medicine</i> , 2017 , 87-104	0.1	
368	Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort. <i>BMJ Open</i> , 2017 , 7, e016627	3	27
367	Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies. <i>Europace</i> , 2017 , 19, 4-15	3.9	88
366	Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. <i>European Heart Journal</i> , 2017 , 38, 2137-2149	9.5	162
365	Demographics, treatment and outcomes of atrial fibrillation in a developing country: the population-based Turkish Atrial Fibrillation (TRAF) cohort. <i>Europace</i> , 2017 , 19, 734-740	3.9	5
364	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. <i>Heart Rhythm</i> , 2017 , 14, e445-e494	6.7	72
363	Special considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillation. <i>Clinical Cardiology</i> , 2017 , 40, 126-131	3.3	15
362	Atrial high-rate episodes and stroke prevention. <i>Europace</i> , 2017 , 19, 169-179	3.9	58
361	Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. <i>BMJ Open</i> , 2017 , 7, e017157	3	58
360	Evolving quality standards for large-scale registries: the GARFIELD-AF experience. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2017 , 3, 114-122	4.6	23
359	The World Heart Federation Roadmap for Nonvalvular Atrial Fibrillation. <i>Global Heart</i> , 2017 , 12, 273-284	2.9	26
358	XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. <i>European Heart Journal</i> , 2016 , 37, 1145-53	9.5	319
357	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial. <i>Europace</i> , 2016 , 18, 6-11	3.9	27
356	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Heart Journal</i> , 2016 , 37, 2893-2962	9.5	4465

355	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>Europace</i> , 2016 , 18, 1609-1678	3.9	1293
354	Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet Neurology</i> , 2016 , 15, 1148-59	24.1	44
353	Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry. <i>International Journal of Cardiology</i> , 2016 , 223, 543-547	3.2	62
352	Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS-ACTS Substudy. <i>Clinical Cardiology</i> , 2016 , 39, 565-569	3.3	27
351	Rivaroxaban real-world evidence: Validating safety and effectiveness in clinical practice. <i>Thrombosis and Haemostasis</i> , 2016 , 116, S13-S23	7	31
350	Medical treatment of stable angina: A tailored therapeutic approach. <i>International Journal of Cardiology</i> , 2016 , 220, 445-53	3.2	25
349	The Ventricular Ectopic QRS Interval: A Potential Marker for Ventricular Arrhythmia in Ischemic Heart Disease. <i>JACC: Clinical Electrophysiology</i> , 2016 , 2, 587-595	4.6	3
348	Stakeholders in NOACs prescription: authors' reply. <i>Europace</i> , 2016 , 18, 788-9	3.9	1
347	Individualized approaches to thromboprophylaxis in atrial fibrillation. <i>American Heart Journal</i> , 2016 , 173, 143-58	4.9	9
346	Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VerT trial. <i>Europace</i> , 2016 , 18, 184-90	3.9	27
345	Assessment of palpitations. <i>BMJ</i> , 2016 , 352, h5649	5.9	10
344	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2016 , 18, 37-50	3.9	90
343	Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. <i>PLoS ONE</i> , 2016 , 11, e0164076	3.7	90
342	Managing reversal of direct oral anticoagulants in emergency situations. Anticoagulation Education Task Force White Paper. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 1003-1010	7	36
341	Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. <i>Revista Española De Cardiología</i> , 2016 , 69, 1167.e1-1167.e85	1.5	91
340	Management of stable angina: A commentary on the European Society of Cardiology guidelines. <i>European Journal of Preventive Cardiology</i> , 2016 , 23, 1401-12	3.9	22
339	Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR. <i>Heart Rhythm</i> , 2016 , 13, 1777-83	6.7	19
338	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2016 , 50, e1-e88	3	589

337	Ranolazine in the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following An Electrical Cardioversion) study. <i>Heart Rhythm</i> , 2015 , 12, 872-8	6.7	55
336	Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. <i>Europace</i> , 2015 , 17, 1007-17	3.9	40
335	COR-ART: A multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate single oral doses of vanoxerine for conversion of recent-onset atrial fibrillation or flutter to normal sinus rhythm. <i>Heart Rhythm</i> , 2015 , 12, 1105-12	6.7	16
334	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology	3.9	426
333	Unresolved issues in the management of chronic stable angina. <i>International Journal of Cardiology</i> , 2015 , 201, 200-7	3.2	19
332	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2015 , 17, 1467-507	3.9	803
331	The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015 , 8, 1048-56	6.4	106
330	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015 , 4, 386	4.3	8
329	Anticoagulation in Atrial Fibrillation - Current Concepts. <i>Arrhythmia and Electrophysiology Review</i> , 2015 , 4, 100-7	3.2	4
328	Rationale and design of the eXplore the efficacy and safety of once-daily oral rivaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTtrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion.	4.9	22
327	Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. <i>Lancet, The</i> , 2014 , 383, 955-62	40	2823
326	Non-pharmacological modulation of the autonomic tone to treat heart failure. <i>European Heart Journal</i> , 2014 , 35, 77-85	9.5	50
325	Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. <i>European Heart Journal</i> , 2014 , 35, 3346-55	9.5	278
324	Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches?. <i>Journal of the American Heart Association</i> , 2014 , 3,	6	33
323	Edoxaban: an update on the new oral direct factor Xa inhibitor. <i>Drugs</i> , 2014 , 74, 1209-31	12.1	75
322	Essentials of Atrial Fibrillation 2014 ,		1
321	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. <i>Europace</i> , 2014 , 16, 1655-73	3.9	77
320	Left atrial appendage closure: a new technique for clinical practice. <i>Heart Rhythm</i> , 2014 , 11, 514-21	6.7	25

319	Early management of atrial fibrillation to prevent cardiovascular complications. <i>European Heart Journal</i> , 2014 , 35, 1448-56	9.5	128
318	Non-vitamin K antagonist oral anticoagulants: an appeal for consensus on terminology. <i>Chest</i> , 2014 , 145, 1177-1178	5.3	15
317	XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. <i>Vascular Health and Risk Management</i> , 2014 , 10, 425-34	4.4	23
316	Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). <i>European Heart Journal</i> , 2014 , 35, 508-16	9.5	278
315	Interaction between digoxin and dronedarone in the PALLAS trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014 , 7, 1019-25	6.4	57
314	Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications. <i>American Heart Journal</i> , 2014 , 168, 632-44	4.9	127
313	Author reply: To PMID 23625942. <i>Europace</i> , 2014 , 16, 151-2	3.9	1
312	Oral anticoagulants for Asian patients with atrial fibrillation. <i>Nature Reviews Cardiology</i> , 2014 , 11, 290-303	14.8	27
311	What is 'valvular' atrial fibrillation? A reappraisal. <i>European Heart Journal</i> , 2014 , 35, 3328-35	9.5	123
310	Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation. <i>Clinical Cardiology</i> , 2014 , 37, 32-47	3.3	64
309	An explanation of recommendation differences: illustrations from recent atrial fibrillation guidelines. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2014 , 37, 116-27	1.6	4
308	Atrial fibrillation. Cryptogenic stroke--can we abandon this apologetic diagnosis?. <i>Nature Reviews Cardiology</i> , 2014 , 11, 504-5	14.8	1
307	Health-related quality of life in patients with atrial fibrillation treated with rhythm control versus rate control: insights from a prospective international registry (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation: RECORD-AF). <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014 , 7, 896-904	5.8	33
306	Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines. <i>Europace</i> , 2014 , 16, 162-73	3.9	55
305	The Role of Continuous Monitoring in Atrial Fibrillation Management. <i>Arrhythmia and Electrophysiology Review</i> , 2014 , 3, 48-50	3.2	7
304	Stroke Prevention in Atrial Fibrillation - Outcomes and Future Directions. <i>Arrhythmia and Electrophysiology Review</i> , 2014 , 3, 194-200	3.2	1
303	The vernakalant story: how did it come to approval in Europe and what is the delay in the U.S.A?. <i>Current Cardiology Reviews</i> , 2014 , 10, 309-14	2.4	15
302	An update and current expert opinions on percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation. <i>Europace</i> , 2013 , 15, 652-6	3.9	32

301	Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. <i>Europace</i> , 2013 , 15, 1407-11	3.9	77
300	Atrial fibrillation guidelines across the Atlantic: a comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/American College of Chest Physicians and the Canadian Cardiovascular Society. <i>Europace</i> , 2013 , 15, 1397-1406	9.5	51
299	Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2013 , 15, 1540-56	3.9	101
298	Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. <i>American Heart Journal</i> , 2013 , 166, 442-8	4.9	102
297	Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease. <i>International Journal of Cardiology</i> , 2013 , 166, 147-51	3.2	22
296	European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2013 , 15, 625-51	3.9	622
295	Actualizaci3n detallada de las gu3as de la ESC para el manejo de la fibrilaci3n auricular de 2012: Actualizaci3n de las gu3as de la Sociedad Europea de Cardiolog3a (ESC) para el manejo de la fibrilaci3n auricular de 2010 Elaborada en colaboraci3n con la Asociaci3n Europea del Ritmo Cardiac. <i>Revista Espanola De Cardiologia</i> , 2013 , 66, 54.e1-54.e24	1.5	10
294	An assessment of the reporting quality of randomised controlled trials relating to anti-arrhythmic agents (2002-2011). <i>International Journal of Cardiology</i> , 2013 , 168, 1393-6	3.2	12
293	Managing anticoagulation for atrial fibrillation: current issues and future strategies. <i>Journal of Internal Medicine</i> , 2013 , 273, 31-41	10.8	7
292	A proposal for interdisciplinary, nurse-coordinated atrial fibrillation expert programmes as a way to structure daily practice. <i>European Heart Journal</i> , 2013 , 34, 2725-30	9.5	58
291	Atrial fibrillation and the 'other drug problem': reducing non-adherence with technology. <i>European Heart Journal</i> , 2013 , 34, 2031-3	9.5	7
290	2012 focused update of the ESC Guidelines for the management of atrial fibrillation[Eur Heart J (2012); 33(21):2719-2747]. <i>European Heart Journal</i> , 2013 , 34, 790-790	9.5	11
289	Managing atrial fibrillation in the global community: The European perspective. <i>Global Cardiology Science & Practice</i> , 2013 , 2013, 173-84	0.7	6
288	EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. <i>European Heart Journal</i> , 2013 , 34, 2094-106	9.5	281
287	The long and short of antiarrhythmic drug treatment. <i>Lancet, The</i> , 2012 , 380, 198-200	4.0	1
286	2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. <i>Europace</i> , 2012 , 14, 528-606	3.9	1160
285	Cardiac arrhythmias--trials and tribulations. <i>Lancet, The</i> , 2012 , 380, 1448-51	4.0	1
284	2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the E. <i>Heart Rhythm</i> , 2012 , 9, 632-696.e21	6.7	1314

283	2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. <i>Europace</i> , 2012 , 14, 1385-413	3.9	1019
282	Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort: clinical correlates and the effect of rhythm-control therapy. <i>American Heart Journal</i> , 2012 , 163, 887-93	4.9	73
281	Antiarrhythmic drugs for the maintenance of sinus rhythm: risks and benefits. <i>International Journal of Cardiology</i> , 2012 , 155, 362-71	3.2	51
280	Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data. <i>CNS Drugs</i> , 2012 , 26, 351-65	6.7	33
279	A proposal for new clinical concepts in the management of atrial fibrillation. <i>American Heart Journal</i> , 2012 , 164, 292-302.e1	4.9	39
278	Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 841-50	15.1	87
277	2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. <i>European Heart Journal</i> , 2012 , 33, 2719-47	9.5	2638
276	Atrial fibrillation and risk. <i>Clinical Cardiology</i> , 2012 , 35 Suppl 1, 1-2	3.3	5
275	Usefulness of continuous electrocardiographic monitoring for atrial fibrillation. <i>American Journal of Cardiology</i> , 2012 , 110, 270-6	3	94
274	Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2012 , 14, 8-27	3.9	156
273	Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial. <i>Europace</i> , 2012 , 14, 804-9	3.9	123
272	Medical treatment of atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2012 , 13, 97-107	1.9	16
271	A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 313-21	15.1	194
270	Real-life observations of clinical outcomes with rhythm- and rate-control therapies for atrial fibrillation RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation). <i>Journal of the American College of Cardiology</i> , 2011 , 58, 493-501	15.1	124
269	Edoxaban: a new oral direct factor xa inhibitor. <i>Drugs</i> , 2011 , 71, 1503-26	12.1	77
268	Dronedarone in high-risk permanent atrial fibrillation. <i>New England Journal of Medicine</i> , 2011 , 365, 2268-76	5.2	438
267	Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. <i>Europace</i> , 2011 , 13, 308-28	3.9	190
266	Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. <i>Europace</i> , 2011 , 13, 610-25	3.9	144

265	Rapid pulmonary vein isolation combined with autonomic ganglia modification: a randomized study. <i>Heart Rhythm</i> , 2011 , 8, 672-8	6.7	167
264	Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 1012-9	7	60
263	Regulatory pathways for development of antiarrhythmic drugs for management of atrial fibrillation/flutter. <i>Europace</i> , 2011 , 13, 1063-76	3.9	7
262	Polyunsaturated fatty acids for prevention of atrial fibrillation: a 'fishy' story. <i>Europace</i> , 2011 , 13, 149-52	3.9	11
261	Implantable cardioverter-defibrillator utilization. <i>Europace</i> , 2011 , 13, 448	3.9	11
260	Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. <i>Europace</i> , 2011 , 13, 723-46	3.9	166
259	Aubrey Leatham and the introduction of cardiac pacing to the UK. <i>Europace</i> , 2010 , 12, 1356-9	3.9	4
258	European utilization of the implantable defibrillator: has 10 years changed the 'enigma'?. <i>Europace</i> , 2010 , 12, 1063-9	3.9	101
257	Upstream therapies after pulmonary vein ablation: five negative studies--what's next?. <i>Europace</i> , 2010 , 12, 1509-13	3.9	5
256	Atrial fibrillation-the final frontier. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2010 , 15, 36S-50S	2.6	6
255	Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2010 , 31, 2369-429	9.5	3452
254	Guías de práctica clínica para el manejo de la fibrilación auricular. <i>Revista Espanola De Cardiologia</i> , 2010 , 63, 1483	1.5	5
253	Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). <i>Europace</i> , 2010 , 12, 1360-420	3.9	1120
252	An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality. <i>Europace</i> , 2010 , 12, 626-33	3.9	89
251	Postoperative atrial fibrillation - what do we really know?. <i>Current Vascular Pharmacology</i> , 2010 , 8, 553-73	3.3	35
250	Dronedarone (Multaq): a new option in atrial fibrillation. <i>The Prescriber</i> , 2010 , 21, 30-34	0.4	
249	Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2010 , 381, 1-13	3.4	38
248	The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation. <i>American Journal of Cardiology</i> , 2010 , 105, 687-93	3	84

247	Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis. <i>Clinical Therapeutics</i> , 2010 , 32, 426-36	3.5	34
246	The RE-LY study: Randomized Evaluation of Long-term anticoagulant therapy: dabigatran vs. warfarin. <i>European Heart Journal</i> , 2009 , 30, 2554-5	9.5	20
245	Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. <i>Europace</i> , 2009 , 11, 860-85	3.9	84
244	Dronedarone: a new option in atrial fibrillation. <i>Future Prescriber</i> , 2009 , 10, 24-32		1
243	Current concepts in the pathogenesis of atrial fibrillation. <i>American Heart Journal</i> , 2009 , 157, 243-52	4.9	137
242	If inhibition with ivabradine : electrophysiological effects and safety. <i>Drug Safety</i> , 2008 , 31, 95-107	5.1	87
241	Treatment of atrial fibrillation. <i>British Medical Bulletin</i> , 2008 , 88, 75-94	5.4	31
240	Safety considerations in the pharmacological management of atrial fibrillation. <i>International Journal of Cardiology</i> , 2008 , 127, 299-306	3.2	48
239	Rhythm control versus rate control for atrial fibrillation and heart failure. <i>New England Journal of Medicine</i> , 2008 , 358, 2667-77	59.2	1090
238	Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. <i>Europace</i> , 2008 , 10, 647-65	3.9	94
237	Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. <i>Circulation</i> , 2008 , 117, 1518-25	16.7	257
236	Successful treatment of heart failure with devices requires collaboration. <i>European Journal of Heart Failure</i> , 2008 , 10, 1229-35	12.3	21
235	Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008 , 5, 30-41		64
234	New antiarrhythmic drugs for atrial fibrillation: focus on dronedarone and vernakalant. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2008 , 23, 7-14	2.4	19
233	Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2008 , 29, 2276-315	9.5	2125
232	Update on atrial fibrillation: part II. <i>Clinical Cardiology</i> , 2008 , 31, 102-8	3.3	14
231	Update on atrial fibrillation: part I. <i>Clinical Cardiology</i> , 2008 , 31, 55-62	3.3	77
230	Comparison of Distributions of Ventricular Periods During Paroxysmal Atrial Fibrillation and Sinus Rhythm 2008 , 3, 95-102		

229 Atrial Ectopics Prior to Atrial Fibrillation Onset **2008**, 3, 115-118

228 Outcome parameters for trials in atrial fibrillation: executive summary. *European Heart Journal*, **2007**, 28, 2803-17 9.5 267

227 Do corticosteroids prevent atrial fibrillation after cardiac surgery?. *Nature Clinical Practice Cardiovascular Medicine*, **2007**, 4, 592-3 10

226 The cost of implantable defibrillators: perceptions and reality. *European Heart Journal*, **2007**, 28, 392-7 9.5 30

225 Some patients with paroxysmal atrial fibrillation should carry flecainide or propafenone to self treat. *BMJ, The*, **2007**, 334, 637 5.9 8

224 Cardiovascular outcomes with atrial-based pacing compared with ventricular pacing: meta-analysis of randomized trials, using individual patient data. *Circulation*, **2006**, 114, 11-7 16.7 182

223 New insights into the initiation of atrial fibrillation: a detailed intraindividual and interindividual analysis of the spontaneous onset of atrial fibrillation using new diagnostic pacemaker features. *Circulation*, **2006**, 113, 1933-41 16.7 48

222 Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. *European Heart Journal*, **2006**, 27, 1341-81 9.5 981

221 Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database. *Journal of the American College of Cardiology*, **2006**, 48, 471-7 15.1 37

220 ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). *Circulation*, **2006**, 114, 1-62 15.1 865

219 ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. *Europace*, **2006**, 8, 651-745 3.9 530

218 Current strategies in the management of atrial fibrillation. *Annals of Thoracic Surgery*, **2006**, 82, 357-64 2.7 27

217 Medical management of atrial fibrillation: state of the art. *Journal of Cardiovascular Electrophysiology*, **2006**, 17 Suppl 2, S2-6 2.7 14

216 Comparison of the effects of a selective IF current inhibitor ivabradine and atenolol on the QT interval in patients with coronary artery disease. *Heart Rhythm*, **2005**, 2, S145-S146 6.7 4

215 Clinical trial design to evaluate the effects of drugs on cardiac repolarization: current state of the art. *Heart Rhythm*, **2005**, 2, S23-9 6.7 27

214 Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. *European Heart Journal*, **2005**, 26, 2422-34 9.5 613

213 Single-chamber versus dual-chamber pacing for high-grade atrioventricular block. *New England Journal of Medicine*, **2005**, 353, 145-55 59.2 273

212 Atrial Tachycardia, Flutter, and Fibrillation **2005**, 283-363 6

211	'Atrial fibrillation--an end to the epidemic?'. <i>Circulation</i> , 2005 , 112, iii	16.7	4
210	Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. <i>Circulation</i> , 2004 , 109, 990-6	16.7	182
209	Association of anti-heart shock protein 65 antibodies with development of postoperative atrial fibrillation. <i>Circulation</i> , 2004 , 110, 2588-90	16.7	39
208	Atrial fibrillation and heart failure: natural history and pharmacological treatment. <i>Europace</i> , 2004 , 5 Suppl 1, S5-19	3.9	76
207	Advances in antiarrhythmic drug treatment of atrial fibrillation: where do we stand now?. <i>Heart Rhythm</i> , 2004 , 1, 244-6	6.7	36
206	The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 1211-6	15.1	59
205	Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. <i>Drugs</i> , 2004 , 64, 1757-65	12.1	284
204	Drug induced QT prolongation and torsades de pointes. <i>British Heart Journal</i> , 2003 , 89, 1363-72		650
203	The results of pacing trials for the prevention and termination of atrial tachyarrhythmias: is there any evidence of therapeutic breakthrough?. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003 , 8, 103-15	2.4	26
202	Rationale and patient selection for "hybrid" drug and device therapy in atrial and ventricular arrhythmias. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003 , 9, 207-14	2.4	6
201	Translation of clinical trials into clinical practice: use of results in formulating guidelines. <i>Journal of Cardiovascular Electrophysiology</i> , 2003 , 14, S9-14	2.7	1
200	Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. <i>Drugs in R and D</i> , 2003 , 4, 83-9	3.4	107
199	Sinus tachyarrhythmias and the specific bradycardic agents: a marriage made in heaven?. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2003 , 8, 89-105	2.6	39
198	The design and conduct of human studies to detect and quantify QT interval prolongation induced by new chemical entities. <i>Fundamental and Clinical Pharmacology</i> , 2002 , 16, 141-5	3.1	5
197	Minimizing the Risks Associated with Significant QTc Prolongation in People with Schizophrenia: A Consensus Statement by The Cardiac Safety in Schizophrenia Group. <i>Australasian Psychiatry</i> , 2002 , 10, 115-124	1.7	10
196	Rate versus rhythm control: is the debate over?. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2002 , 7, 7-11	2.4	2
195	Identification and catheter ablation of extracardiac and intracardiac components of ligament of Marshall tissue for treatment of paroxysmal atrial fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2001 , 12, 750-8	2.7	75
194	Impact of electrocardiogram recording format on QT interval measurement and QT dispersion assessment. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2001 , 24, 1739-47	1.6	13

193	Significance of circulatory epinephrine levels in exercise-induced neurally mediated syncope. <i>Clinical Cardiology</i> , 2001 , 24, 15-20	3.3	12
192	Evaluating the place of low-molecular-weight heparin in the management of acute coronary syndromes. A panel discussion with audience participation. <i>Clinical Cardiology</i> , 2001 , 24, 120-2	3.3	1
191	Pathophysiology and prevention of atrial fibrillation. <i>Circulation</i> , 2001 , 103, 769-77	16.7	562
190	New descriptors of homogeneity of the propagation of ventricular repolarization. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2000 , 23, 1968-72	1.6	15
189	Short-, mid-, and long-term reproducibility of the atrial signal-averaged electrocardiogram in healthy subjects: comparison with the conventional ventricular signal-averaged electrocardiogram. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2000 , 23, 122-7	1.6	9
188	Consistency of multicenter measurements of heart rate variability in survivors of acute myocardial infarction. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2000 , 23, 157-64	1.6	8
187	QT dispersion does not represent electrocardiographic interlead heterogeneity of ventricular repolarization. <i>Journal of Cardiovascular Electrophysiology</i> , 2000 , 11, 835-43	2.7	129
186	Wavelet Analysis of Signal-Averaged Electrocardiograms. <i>Annals of Noninvasive Electrocardiology</i> , 2000 , 5, 4-19	1.5	3
185	Agreement Between Automatic and Manual Measurement of Atrial and Ventricular Signal-Averaged Electrocardiograms in Healthy Subjects. <i>Annals of Noninvasive Electrocardiology</i> , 2000 , 5, 133-138	1.5	
184	Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2000 , 4, 369-82	2.4	239
183	Atrial pacing to prevent atrial fibrillation?. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2000 , 4 Suppl 1, 149-53	2.4	6
182	Correlation of coronary angiography with "tombstoning" electrocardiographic pattern in patients after acute myocardial infarction. <i>Clinical Cardiology</i> , 2000 , 23, 347-52	3.3	16
181	Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. <i>Lancet, The</i> , 2000 , 356, 2052-8	4.0	276
180	Spontaneous episodes of atrial fibrillation after implantation of the Metrix Atrioverter: observations on treated and nontreated episodes. Metrix Investigators. <i>Journal of the American College of Cardiology</i> , 2000 , 35, 1428-33	15.1	55
179	The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 1303-9	15.1	446
178	Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. <i>New England Journal of Medicine</i> , 1999 , 341, 857-65	59.2	799
177	Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. <i>Circulation</i> , 1999 , 99, 2268-75	16.7	194
176	Evaluation of antiarrhythmic drug efficacy in patients with an ICD: unlimited potential or replete with complexity and problems?. <i>Journal of Cardiovascular Electrophysiology</i> , 1999 , 10, 1534-49	2.7	5

175	What should we expect from the next generation of antiarrhythmic drugs?. <i>Journal of Cardiovascular Electrophysiology</i> , 1999 , 10, 307-17	2.7	24
174	Circadian Pattern of QT/RR Adaptation in Patients with and Without Sudden Cardiac Death after Myocardial Infarction. <i>Annals of Noninvasive Electrocardiology</i> , 1999 , 4, 286-294	1.5	10
173	Relation of ventricular repolarization to cardiac cycle length in normal subjects, hypertrophic cardiomyopathy, and patients with myocardial infarction. <i>Clinical Cardiology</i> , 1999 , 22, 649-54	3.3	27
172	Treatment of arrhythmias in heart failure. <i>European Journal of Heart Failure</i> , 1999 , 1, 133-7	12.3	2
171	Clinical Implications of the European Myocardial Infarct Amiodarone Trial (EMIAT). <i>Journal of Interventional Cardiac Electrophysiology</i> , 1998 , 2, 26-27		
170	Quinidine in Atrial Fibrillation and Ventricular Tachycardia. <i>Journal of Interventional Cardiac Electrophysiology</i> , 1998 , 2, 207-210		
169	Clinical Implications of the European Myocardial Infarct Amiodarone Trial (EMIAT). <i>Journal of Interventional Cardiac Electrophysiology</i> , 1998 , 2, 236-237		
168	Optimum lead positioning for recording bipolar atrial electrocardiograms during sinus rhythm and atrial fibrillation. <i>Clinical Cardiology</i> , 1998 , 21, 825-30	3.3	15
167	Initiating sequences in exercise induced idiopathic ventricular tachycardia of left bundle branch-like morphology. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1998 , 21, 1873-80	1.6	9
166	Stepwise strategy on the cost of risk stratification after acute myocardial infarction: a retrospective simulation study. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1998 , 21, 603-9	1.6	3
165	Long-term effect of VVI pacing on atrial and ventricular function in patients with sick sinus syndrome. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1998 , 21, 728-34	1.6	18
164	Schemes of classification. Replace a number of complicated systems with a simple division of atrial fibrillation (AF) based on temporal pattern. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1998 , 21, 776-7	1.6	2
163	Myocardial injury induced by radiofrequency and low energy ablation: a quantitative study of CK isoforms, CK-MB, and troponin-T concentrations. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1998 , 21, 1410-6	1.6	31
162	Mid- and long-term similarity of ventricular response to paroxysmal atrial fibrillation: digoxin versus placebo. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1998 , 21, 1735-40	1.6	2
161	A relationship between fluctuations in heart rate and the duration of subsequent episodes of atrial fibrillation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1998 , 21, 181-5	1.6	11
160	Multiparametric analysis of heart rate variability used for risk stratification among survivors of acute myocardial infarction. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1998 , 21, 186-92	1.6	84
159	QT interval and QT dispersion measured with the threshold method depend on threshold level. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1998 , 21, 2372-5	1.6	19
158	Circadian variation in atrial fibrillation in patients with frequent paroxysms. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1998 , 21, 2445-9	1.6	10

157	Evolution of changes in the ventricular rhythm during paroxysmal atrial fibrillation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1998 , 21, 2450-4	1.6	3
156	Age and gender influences on rate and duration of paroxysmal atrial fibrillation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1998 , 21, 2455-8	1.6	60
155	Classification of atrial fibrillation. <i>American Journal of Cardiology</i> , 1998 , 82, 18N-28N	3	80
154	Atrioverter: an implantable device for the treatment of atrial fibrillation. <i>Circulation</i> , 1998 , 98, 1651-6	16.7	222
153	Exercise-induced T-wave alternans as a marker of high risk in patients with hypertrophic cardiomyopathy. <i>Japanese Circulation Journal</i> , 1997 , 61, 650-6		47
152	Dual-chamber pacing produced modest symptomatic and hemodynamic improvements in patients with hypertrophic cardiomyopathy. <i>Evidence-based Cardiovascular Medicine</i> , 1997 , 1, 73		
151	Initial clinical experience with an implantable human atrial defibrillator. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1997 , 20, 220-5	1.6	63
150	Graphical representation of complex data--diurnal patterns of initiations of atrial fibrillation episodes. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1997 , 20, 2848-52	1.6	1
149	Performance of basic ventricular tachycardia detection algorithms in implantable cardioverter defibrillators: implications for device programming. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1997 , 20, 2975-83	1.6	17
148	Repolarization alternans: techniques, mechanisms, and cardiac vulnerability. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1997 , 20, 2641-57	1.6	23
147	Tachycardia-induced atrial myopathy: an important mechanism in the pathophysiology of atrial fibrillation?. <i>Journal of Cardiovascular Electrophysiology</i> , 1997 , 8, 1065-74	2.7	27
146	Gender Specificities in Risk Stratification After Myocardial Infarction. <i>Annals of Noninvasive Electrocardiology</i> , 1997 , 2, 59-68	1.5	1
145	Clinical relevance of heart rate variability. <i>Clinical Cardiology</i> , 1997 , 20, 162-8	3.3	29
144	Long-term management of atrial fibrillation. <i>Clinical Cardiology</i> , 1997 , 20, 381-90	3.3	5
143	Role of Invasive Electrophysiology Testing in the Evaluation and Management of Idiopathic Ventricular Fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 1997 , 1, 452-456		
142	Technical Advances in Signal-Averaged Electrocardiography. <i>Journal of Interventional Cardiac Electrophysiology</i> , 1997 , 1, 317-320		1
141	Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. <i>Lancet, The</i> , 1996 , 348, 7-12	40	1115
140	Chronotropic incompetence--Part I: Normal regulation of the heart rate. <i>Clinical Cardiology</i> , 1996 , 19, 424-8	3.3	28

139	Chronotropic incompetence--Part II: Clinical implications. <i>Clinical Cardiology</i> , 1996 , 19, 503-8	3.3	33
138	Atrial fibrillation in the elderly. <i>Clinical Cardiology</i> , 1996 , 19, 765-75	3.3	23
137	Stepwise strategy of using short- and long-term heart rate variability for risk stratification after myocardial infarction. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1996 , 19, 1845-51	1.6	27
136	Effect of digoxin on the ventricular rate variability during paroxysmal atrial fibrillation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1996 , 19, 1968-71	1.6	8
135	Identification of electrocardiographic patterns. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1996 , 19, 245-51	1.6	8
134	Changes of QT intervals associated with postural change in patients with chronic atrial fibrillation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1996 , 19, 490-5	1.6	6
133	Predictive Power of Heart Rate Variability Used as a Stratifier of Cardiac Mortality After Myocardial Infarction in Patients Discharged With and Without Beta-Blocker Therapy. <i>Annals of Noninvasive Electrocardiology</i> , 1996 , 1, 12-18	1.5	1
132	Interobserver Reproducibility of QT Interval Measurement and QT Dispersion in Patients After Acute Myocardial Infarction. <i>Annals of Noninvasive Electrocardiology</i> , 1996 , 1, 363-374	1.5	24
131	Algebraic decomposition of the TU wave morphology patterns. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1995 , 18, 2209-15	1.6	11
130	Identification of atrial fibrillation episodes in ambulatory electrocardiographic recordings: validation of a method for obtaining labeled R-R interval files. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1995 , 18, 1315-20	1.6	27
129	Influence of the infarct site on the identification of patients with ventricular tachycardia after myocardial infarction based on the time-domain and spectral turbulence analysis of the signal-averaged electrocardiogram. <i>Clinical Cardiology</i> , 1995 , 18, 39-44	3.3	3
128	Antiarrhythmic drug classifications and the clinician: a gambit in the land of chaos. <i>Clinical Cardiology</i> , 1994 , 17, 142-8	3.3	9
127	QT dispersion: problems of methodology and clinical significance. <i>Journal of Cardiovascular Electrophysiology</i> , 1994 , 5, 672-85	2.7	239
126	Alteration of the QT/RR relationship in patients with idiopathic ventricular tachycardia. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1994 , 17, 199-206	1.6	20
125	Risk stratification after myocardial infarction. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1994 , 17, 401-16		12
124	Short- and long-term reproducibility of QT, QTc, and QT dispersion measurement in healthy subjects. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1994 , 17, 928-37	1.6	186
123	Influence of filtering techniques on the time-domain analysis, diagnosis, and clinical use of signal-averaged electrocardiogram. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1994 , 17, 1107-17	1.6	6
122	New algorithms to increase the initial rate response in a minute volume rate adaptive pacemaker. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1994 , 17, 1960-5	1.6	10

121	A new pacing algorithm for overdrive suppression of atrial fibrillation. Chorus Multicentre Study Group. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1994 , 17, 1966-73	1.6	90
120	Relationship between short- and long-term measurements of heart rate variability in patients at risk of sudden cardiac death. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1994 , 17, 2194-200	1.6	13
119	Ambulatory assessment of the QT interval in patients with hypertrophic cardiomyopathy: risk stratification and effect of low dose amiodarone. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1994 , 17, 2222-7	1.6	23
118	Effects of propafenone on calcium currents in single ventricular myocytes of guinea-pig. <i>British Journal of Pharmacology</i> , 1993 , 109, 178-82	8.6	15
117	The response of implanted dual chamber pacemakers to 50 Hz extraneous electrical interference. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1993 , 16, 1966-74	1.6	24
116	New European regulations on medical devices. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1993 , 16, 1427-8	1.6	
115	Are we being driven to two sensors?: clinical benefits of sensor cross-checking. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1993 , 16, 1441-4	1.6	18
114	North American Society of Pacing and Electrophysiology policy statement. The NASPE/BPEG defibrillator code. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1993 , 16, 1776-80	1.6	72
113	NASPE POLICY STATEMENT The NASPE* BPEG** Defibrillator Code. <i>Journal of Interventional Cardiology</i> , 1993 , 6, 235-239	1.8	1
112	AAI pacing mode: when is it indicated and how should it be achieved?. <i>Clinical Cardiology</i> , 1993 , 16, 339-43	3.3	7
111	Atrioventricular junctional reentrant tachycardia utilizing multiple retrograde fibers during ablation of the slow pathway. <i>Clinical Cardiology</i> , 1993 , 16, 889-91	3.3	6
110	Prophylactic pacing for prevention of sudden death in congenital complete heart block?. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1992 , 15, 1526-30	1.6	9
109	Differentiation between monomorphic ventricular tachycardia and sinus tachycardia based on the right ventricular evoked potential. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1992 , 15, 1661-6	1.6	2
108	Prediction of antiarrhythmic efficacy of class I and III agents in patients with ventricular tachycardia by signal-averaged ECG analysis. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1992 , 15, 2116-21	1.6	2
107	Comparison of verapamil and diltiazem in the suppression of idiopathic ventricular tachycardia. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1992 , 15, 2122-6	1.6	23
106	Relationship between spectral measures of heart rate variability and ventricular ectopic activity in patients with idiopathic ventricular tachycardia. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1992 , 15, 2206-10	1.6	6
105	Development of a rate adaptive pacemaker based on the maximum rate-of-rise of right ventricular pressure (RV dP/dtmax). <i>PACE - Pacing and Clinical Electrophysiology</i> , 1992 , 15, 219-34	1.6	31
104	The value of transesophageal atrial pacing in predicting the efficacy of antiarrhythmic drugs in patients with paroxysmal narrow QRS complex tachycardia. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1992 , 15, 895-904	1.6	4

103	Transtelephonic interrogation of the implantable cardioverter defibrillator. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1992 , 15, 1144-50	1.6	11
102	Is hypomagnesemia arrhythmogenic?. <i>Clinical Cardiology</i> , 1992 , 15, 103-8	3.3	48
101	Benefits of the advances in cardiac pacemaker technology. <i>Clinical Cardiology</i> , 1992 , 15, 601-6	3.3	2
100	Critical noise level reduction for correct identification of late potentials: an illustrative case report. <i>Clinical Cardiology</i> , 1991 , 14, 779-83	3.3	1
99	Single-lead VDD pacing: excellence or expedience?. <i>Clinical Cardiology</i> , 1991 , 14, 917-22	3.3	4
98	Cardiac electrophysiological experiments in numero, Part II: Models of electrophysiological processes. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1991 , 14, 1648-71	1.6	3
97	Transcoronary atrioventricular nodal modification using microvascular collagen. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1991 , 14, 1976-80	1.6	2
96	Multifactorial prediction of arrhythmic events after myocardial infarction. Combination of heart rate variability and left ventricular ejection fraction with other variables. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1991 , 14, 1986-91	1.6	12
95	RR variability and baroreflex sensitivity in patients with ventricular tachycardia associated with normal heart and patients with ischemic heart disease. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1991 , 14, 2016-21	1.6	3
94	A comparison of intravenous propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-White syndrome. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1991 , 14, 2028-34	1.6	20
93	The effect of age on the electrophysiological and autonomic correlates of sudden death after acute myocardial infarction. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1991 , 14, 2049-55	1.6	4
92	Can we treat carotid sinus syndrome?. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1991 , 14, 1367-74	1.6	9
91	Influence of propranolol on the ventricular depolarization gradient. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1991 , 14, 787-92	1.6	5
90	Cardiac electrophysiological experiments in numero, Part III: Simulation of arrhythmias and pacing. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1991 , 14, 2167-86	1.6	2
89	The right ventricular outflow tract as an alternative permanent pacing site: long-term follow-up. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1991 , 14, 3-6	1.6	62
88	Adenosine and supraventricular tachycardia. <i>New England Journal of Medicine</i> , 1991 , 325, 1621-9	59.2	198
87	Termination of macro-reentrant tachycardia by a single extrastimulus delivered during the 'effective' refractory period: a computer modeled 'case report'. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1990 , 13, 103-9	1.6	6
86	Ventricular pacing for sick sinus syndrome--a risky business?. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1990 , 13, 695-9	1.6	40

85	A study of the use of flecainide acetate in the long-term management of cardiac arrhythmias. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1990 , 13, 767-75	1.6	12
84	Reliability of minute ventilation as a parameter for rate responsive pacing. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1989 , 12, 321-30	1.6	36
83	Myopotential interference in unipolar rate responsive pacemakers. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1989 , 12, 1324-30	1.6	15
82	Single-Chamber Rate Adaptive Pacing. <i>Journal of Electrophysiology</i> , 1989 , 3, 181-189		4
81	Statistical Distribution of Ventricular Ectopic Beats Assessed by Computer Analysis of Long-Term Electrocardiograms: Problems Related to the Definition of Arrhythmogenesis. <i>Journal of Electrophysiology</i> , 1989 , 3, 261-271		1
80	The development of a system for the evaluation of electromagnetic interference with pacemaker function: hazards in the aircraft environment. <i>Journal of Medical Engineering and Technology</i> , 1989 , 13, 161-5	1.8	6
79	Drug effects on the sinus node. A clinical perspective. <i>Cardiovascular Drugs and Therapy</i> , 1988 , 2, 165-70	3.9	3
78	Computer Modelling of Cardiac Recovery Processes and Repolarization Sequences. <i>Journal of Electrophysiology</i> , 1988 , 2, 335-351		2
77	Theoretical evaluation of the Rosenblueth hypothesis. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1988 , 11, 1250-61	1.6	2
76	Limitations of rate response of an activity-sensing rate-responsive pacemaker to different forms of activity. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1988 , 11, 141-50	1.6	75
75	Comparative evaluation of chronotropic responses of QT sensing and activity sensing rate responsive pacemakers. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1988 , 11, 1405-12	1.6	29
74	Clinical experience with Sensolog 703: a new activity sensing rate responsive pacemaker. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1988 , 11, 1444-55	1.6	33
73	Modification of the DDD pacing mode to prevent junctional reentry tachycardia: computer modelling experiments. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1988 , 11, 1465-78	1.6	5
72	Complexity of AV nodal function: complex nodal structure or complex behavior of nodal elements?. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1988 , 11, 425-33	1.6	9
71	Rate modulation by arm movements of the respiratory dependent rate responsive pacemaker. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1988 , 11, 744-52	1.6	18
70	Initial clinical experience with a minute ventilation sensing rate modulated pacemaker: improvements in exercise capacity and symptomatology. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1988 , 11, 1815-22	1.6	41
69	Computer modeling of cardiac rhythm disturbances and heart-pacemaker interaction. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1988 , 11, 2101-9	1.6	2
68	The NASPE/BPEG generic pacemaker code for antibradyarrhythmia and adaptive-rate pacing and antitachyarrhythmia devices. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1987 , 10, 794-9	1.6	114

67	Ventricular Arrhythmias and Sudden Cardiac Death270-292	
66	Atrial Fibrillation and Other Rhythm Disturbances in the Elderly139-150	
65	Acquired Long QT Syndrome Secondary to Noncardiac Conditions171-181	1
64	Risk of QT Prolongation and Torsades de Pointes with Antihistamines87-101	
63	Acquired Long QT Syndrome Secondary to Cardiac Conditions163-170	
62	Measurement of the QT Interval and Repolarization Assessment24-59	3
61	Introduction to Drug-induced Long QT Syndrome60-68	0
60	Risk of QT Prolongation and Torsades de Pointes with Antiarrhythmic Drugs69-86	0
59	Risk of QT Prolongation and Torsades de Pointes with Antimicrobial and Antimalarial Drugs121-139	
58	Risk of QT Prolongation and Torsades de Pointes with Psychotropic Drugs102-120	
57	Perspective on Drug-induced Repolarization Changes182-190	
56	Risk of QT Prolongation and Torsades de Pointes with Prokinetics and Miscellaneous other Drugs140-162	
55	Mechanisms of Acquired QT Prolongation and Torsades de Pointes8-23	
54	Implantable Devices220-236	
53	QT Prolongation with Quinolone Antimicrobial Agents421-440	1
52	Restenosis: Etiologies and Prevention371-394	1
51	Clinical Trials on Atrial Fibrillation/Future Perspectives137-160	
50	Blood Pressure and Cardiovascular Disease146-160	1

49	The Fetal Origins of Coronary Heart Disease279-286	1
48	Impact of Revascularization Procedures in Chronic Coronary Artery Disease on Clinical Outcomes: A Critical Review of the Evidence339-359	1
47	Acute non-ST-segment Elevation Coronary Syndromes: Unstable Angina and non-ST-segment Elevation Myocardial Infarction397-425	2
46	Management of Overt Heart Failure659-680	1
45	Pericardial Disease: An Evidence-Based Approach to Diagnosis and Treatment735-748	2
44	What is Evidence-Based Cardiology?3-13	
43	Tobacco: Global Burden and Community Solutions103-113	
42	Glucose Abnormalities and Cardiovascular Disease:DysglycemiaAs an Emerging Cardiovascular Risk Factor161-169	
41	Physical Activity and Exercise in Cardiovascular Disease Prevention and Rehabilitation170-180	
40	Psychosocial Factors in the Primary and Secondary Prevention of Coronary Heart Disease: An Updated Systematic Review of Prospective Cohort Studies181-218	1
39	Emerging Approaches in Cardiovascular Prevention219-230	
38	A Critical Appraisal of the Cardiovascular History and Physical Examination14-23	
37	Ethnicity and Cardiovascular Disease259-278	
36	Molecular Genetics of Cardiovascular Disorders287-299	
35	Adjunctive Medical Therapy in Percutaneous Coronary Intervention360-370	
34	Fibrinolytic Therapy426-443	
33	Mechanical Reperfusion Strategies in Patients Presenting with Acute Myocardial Infarction444-455	
32	Adjunctive Antithrombotic Therapy for St-Elevation Acute Myocardial Infarction456-476	

- 31 Pain Relief, General Management, and Other Adjunctive Treatments 477-487
- 30 Complications After Myocardial Infarction 488-506
- 29 Atrial Fibrillation: Non-Pharmacologic Therapies 556-566
- 28 Prevention and Treatment of Life-Threatening Ventricular Arrhythmia and Sudden Death 577-586
- 27 Prevention of Congestive Heart Failure and Treatment of Asymptomatic Left Ventricular Dysfunction 643-658
- 26 Acute Myocarditis and Dilated Cardiomyopathy 681-702
- 25 Other Cardiomyopathies 718-732
- 24 Finding Current Best Evidence to Practice Evidence-Based Cardiology 40-45
- 23 Rheumatic Heart Disease: Prevention and Acute Treatment 751-757
- 22 Indications for Surgery in Aortic Valve Disease 767-781
- 21 Balloon Valvuloplasty: Aortic Valve 782-795
- 20 Valve Repair and Choice of Valves 809-816
- 19 Diagnosis and Management of Infective Endocarditis 817-831
- 18 Antithrombotic Therapy after Heart Valve Replacement 832-836
- 17 Heart Disease and Pregnancy 853-863
- 16 Venous Thromboembolic Disease 864-876
- 15 Clinical Applications of External Evidence 889-891
- 14 Introduction to Decision Analysis 56-70

13 Valvular Heart Disease: Timing of Surgery934-937

12 Assessing and Changing Cardiovascular Clinical Practices71-88

11 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology1-2

10 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology837-838

9 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology887-888

8 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology89-90

7 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology327-328

6 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology395-396

5 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology517-518

4 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology575-576

3 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology641-642

2 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology733-734

1 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology749-750